NeuroScientific Biopharmaceuticals Ltd. announced the company has received approval from the Human Research Ethics Committee (HREC) for its early-phase clinical trial of lead drug candidate EmtinBTM which will be undertaken by leading WA-based clinical research partner Linear Clinical Research. HREC approval for the clinical trial is a significant milestone for NeuroScientific in achieving the landmark outcome of commencing its first clinical trial in first half of 2022. The early-phase clinical trial will include up to 30 healthy volunteers with recruitment of subjects expected to start immediately.

An important focus of this study will involve the assessment of biomarkers in human blood samples that indicate proof of the mechanism of activity of EmtinBTM in humans and can be used to guide efficacy outcomes during future trials in patients.